European Patent Completes IP Protection in Major Markets
Filed with ASX · · 1 page · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Appendix 4C - December 2018 Quarter Cashflow Statement
- App 4D Half Year Accounts 30 Sep 2018
- Appendix 4C - quarterly
- Response to ASX Query
- Appendix 4C - June 2018 Quarter Cashflow Statement
Later from Amplia Therapeutics
- Appendix 4C - Quarterly Statement of Cash Flows
- Preliminary Final Report - Year Ended 31 March 2019
- Capital Raising for Clinical-Enabling Studies
- Dr John Lambert appointed as new CEO
- Rights Issue Prospectus
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics